Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about VRTX
Recent news which mentions VRTX
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
32
33
Next >
Market Whales and Their Recent Bets on VRTX Options
January 17, 2024
Tickers
VRTX
Tags
VRTX
Markets
Options
From
Benzinga
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
Tickers
BLUE
CRSP
NEWS
VRTX
Tags
News
FDA
Briefs
From
Benzinga
The Best Stock to Invest $1,000 in Right Now
January 17, 2024
Tickers
VRTX
Tags
VRTX
Market News
Recent Press Releases
From
Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Tickers
ARQT
HUM
ILMN
IMCR
Tags
PFE
VRTX
IMCR
From
Benzinga
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
January 15, 2024
Tickers
CRSP
VRTX
Tags
VRTX
Market News
CRSP
From
Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
January 15, 2024
Tickers
CRSP
EDIT
VRTX
Tags
EDIT
VRTX
CRSP
From
Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2024
January 14, 2024
Tickers
AMZN
BEP
BEPC
CRSP
Tags
GOOG
MSFT
Market News
From
Motley Fool
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
January 14, 2024
Tickers
GOOG
GOOGL
MELI
VRTX
Tags
GOOGL
GOOG
Recent Press Releases
From
Motley Fool
3 Unstoppable Stocks to Buy in 2024
January 13, 2024
Tickers
LLY
NVO
VRTX
Tags
NVO
Recent Press Releases
Market News
From
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
January 13, 2024
Tickers
ARKK
CRSP
RXRX
SQ
Tags
Market News
SQ
ARKK
From
Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
January 12, 2024
Tickers
ABT
NEWS
UBER
URNM
Tags
UBER
Top Stories
Brenda Vingiello
From
Benzinga
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
Tickers
BEAM
EDIT
LLY
VERV
Tags
VERV
NASDAQ:EDIT,NASDAQ:VRTX,NASDAQ:BEAM,NASDAQ:VERV,NYSE:LLY
VRTX
From
InvestorPlace
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
January 11, 2024
Tickers
VRTX
Tags
Options
BZI/UOA
Market News
From
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 10, 2024
Tickers
ABBV
ANVS
BMEA
CVS
Tags
ABBV
Market News
Benzinga
From
Benzinga
2 Red Flags for Bluebird Bio Stock
January 10, 2024
Tickers
BLUE
CRSP
VRTX
Tags
Market News
CRSP
BLUE
From
Motley Fool
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend
January 10, 2024
Tickers
AXON
TTD
VRTX
Tags
VRTX
TTD
Recent Press Releases
From
Motley Fool
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts
January 09, 2024
Tickers
VRTX
Tags
Analyst Ratings
Market News
Benzinga
From
Benzinga
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
January 09, 2024
Tickers
NEWS
VRTX
Tags
VRTX
Markets
BZI/PE
From
Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
January 08, 2024
Tickers
NEWS
VRTX
Tags
BZI/POD
Benzinga
Market News
From
Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
Tickers
ABBV
AMGN
BMY
CERE
Tags
VRTX
CERE
SRPT
From
Benzinga
The Ultimate Growth Stock to Buy With $1,000 Right Now
January 08, 2024
Tickers
CRSP
VRTX
Tags
CRSP
Market News
Recent Press Releases
From
Motley Fool
5 Top Stocks to Buy in January
January 07, 2024
Tickers
BIP
BIPC
IBM
NFLX
Tags
IBM
BIPC
Market News
From
Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Now?
January 06, 2024
Tickers
VRTX
Tags
VRTX
Recent Press Releases
Market News
From
Motley Fool
Investing Trends to Follow in 2024
January 06, 2024
Tickers
AMT
BRK-A
BRK-B
DIS
Tags
BRK/A
BRK/B
META
From
Motley Fool
2 Biotech Stocks With Huge Catalysts in 2024
January 05, 2024
Tickers
AMLX
CRSP
VRTX
Tags
CRSP
Market News
Recent Press Releases
From
Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
January 04, 2024
Tickers
BUD
BYD
CRSP
DIS
Tags
Market News
META
UBER
From
InvestorPlace
The Best Stocks to Invest $1,000 in Right Now
January 04, 2024
Tickers
LLY
NVO
VRTX
Tags
Recent Press Releases
NVO
LLY
From
Motley Fool
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
January 04, 2024
Tickers
CRSP
VRTX
Tags
Recent Press Releases
Market News
CRSP
From
Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
January 03, 2024
Tickers
CRSP
ISRG
VRTX
Tags
NASDAQ:CRSP,NASDAQ:VRTX,NASDAQ:ISRG
VRTX
ISRG
From
InvestorPlace
January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.
January 03, 2024
Tickers
BEP
BEPC
MELI
VRTX
Tags
BEP
VRTX
MELI
From
Motley Fool
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.